- Indications and Usage For adults to control blood glucose; for the treatment of adults with obesity or overweight (body mass index [BMI] ≥27 kg/m²) associated with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or hyperlipidemia, as an adjunct to a reduced-calorie diet and increased physical activity.
- Dosage and Administration Dosage Escalation: For glycemic control, start at 0.6 mg once daily. After at least 1 week, increase to 1.2 mg. For further improvement, may increase to 1.8 mg after at least 1 week (maximum daily dose is 1.8 mg). For weight management, start at 0.6 mg and titrate weekly to 3.0 mg. Administration: Subcutaneous injection once daily at any time of day, independent of meals. Inject into the abdomen, thigh, or upper arm. Missed Dose: If a dose is missed, administer it as soon as remembered, but do not administer two doses on the same day. Dose Adjustment: When combined with a sulfonylurea, consider reducing the dosage of the sulfonylurea to lower the risk of hypoglycemia.
- Mechanism of Action Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It increases glucose-dependent insulin secretion, suppresses glucagon secretion, delays gastric emptying, and promotes satiety.
- Safety and Warnings Thyroid C-cell Tumors: Risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (Black Box Warning). Acute Pancreatitis: If pancreatitis is suspected, discontinue liraglutide immediately. Hypoglycemia: Increased risk when used with sulfonylureas. Gallbladder Disease: Report symptoms of cholelithiasis or cholecystitis (e.g., abdominal pain) immediately.
- Adverse Reactions and Clinical Research Adverse Reactions: The most common adverse reactions are gastrointestinal: nausea and diarrhea (very common), vomiting, constipation, abdominal pain, indigestion, and headache (common). Clinical Research: Clinical trials demonstrated significant improvements in HbA1c and body weight compared to placebo.
- Drug Interactions Sulfonylureas: Concomitant use increases the risk of hypoglycemia; dosage reduction of the sulfonylurea is required. Oral Medications: Since liraglutide delays gastric emptying, it may affect the absorption of orally administered concomitant medications (e.g., reduces peak concentration and delays time to peak of acetaminophen, but does not affect efficacy).
- Pharmaceutical Information Appearance: The solution must be clear and colorless prior to use. Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Package: Typically available as a 3 mL pre-filled injection pen (18 mg/3 mL).
Victoza Liraglutide Injection
Brand Name: 诺和力 ®（Victoza®）
Generic Name: Liraglutide
Strength: 3mL:18mg per prefilled pen, 1 pen per box
Manufacturer: Novo Nordisk A/S (Denmark); Sub-packager: Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Marketing Authorization Holder: Novo Nordisk A/S
Approval Date in China: 2016
Registration Number: 国药准字J20160033
Storage: Store refrigerated at 2°C–8°C before first use; after first use, store below 30°C or refrigerated at 2°C–8°C within 30 days. Do not freeze, protect from light. Refer to the full package insert for detailed storage specifications.
Price&Cost:Contact Us now for the best price of Liraglutide（Victoza）
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.